胰腺癌空间构型与新辅助治疗和根治性切除术后疾病复发相关
Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection.
从标准H&E切片量化的残留癌-间质拓扑结构在PDAC新辅助治疗后产生独立预后信号,为空间风险提供细胞免疫相关性依据,并推动前瞻性验证及空间信息指导的辅助治疗策略。
英文原题:The Detection of Immunity against WT1 and SMAD4(P130L) of EpCAM(+) Cancer Cells in Malignant Pleural Effusion.
在MPE中检测到了对EpCAM+胰腺癌细胞中表达的WT1或SMAD4 P130L新抗原产生应答的CD8+T细胞。
恶性胸腔积液(MPE)提供了一个包含癌细胞和免疫细胞的液体肿瘤微环境模型。然而,肿瘤抗原特异性CD8+ T细胞的特征尚未得到详细研究。在此,我们分析了一位胰腺癌患者在整个疾病过程中(MPE第1次和第2次,MPE第1次后两个月)接受靶向Wilms瘤1(WT1)抗原的树突状细胞疫苗后采集的MPE样本。从MPE第1次到MPE第2次,上皮细胞黏附分子(EpCAM)+癌细胞(PD-L1-或T细胞免疫球蛋白黏蛋白-3,TIM-3-)、PD-1或TIM-3阳性的CD8+ T细胞以及CD14+CD68+CD163+TIM-3+巨噬细胞均增加。WT1特异性细胞毒性淋巴细胞(WT1-CTLs)与MPE CD8+ T细胞的比例以及WT1-CTLs的IFN-γ分泌随疾病进展而降低。同时,WT1-CTLs中中央记忆T(TCM)的比例下降。另一方面,通过HLA-A*11:01限制性SVCVNLYH新抗原的体外扩增,检测到针对SMAD4 P130L(在EpCAM+癌细胞中均一表达)的CD8+ T细胞应答。此外,随着MPE样本中CD8+ TCM数量显著减少,针对SMAD4 P130L的CD8+ T细胞应答减弱。总之,在MPE中检测到针对EpCAM+胰腺癌细胞中表达的WT1或SMAD4 P130L新抗原的CD8+ T细胞。肿瘤抗原特异性免疫应答将为MPE微环境提供新的见解。
Malignant pleural effusion (MPE) provides a liquid tumor microenvironment model that includes cancer cells and immune cells. However, the characteristics of tumor antigen-specific CD8 + T cells have not been investigated in detail. Here, we analyzed MPE samples taken from a patient with pancreatic cancer who received a dendritic cell vaccine targeting Wilms' Tumor 1 (WT1) antigen over the disease course (two points at MPE 1st and 2 nd , two months after MPE1 st ). Epithelial cell adhesion molecule (EpCAM) + cancer cells (PD-L1 - or T cell immunoglobulin mucin-3, TIM-3 - ), both PD-1 or TIM-3 positive CD8 + T cells, and CD14 + CD68 + CD163 + TIM-3 + macrophages increased from the MPE 1st to MPE 2nd . The ratio of WT1-specific cytotoxic lymphocytes (WT1-CTLs) to MPE CD8 + T cells and IFN-γ secretion of WT1-CTLs were reduced with disease progression. Coincidentally, the fraction of central memory T (T CM ) of WT1-CTLs was decreased. On the other hand, CD8 + T cells in response to SMAD4 P130L , which is homogeneously expressed in EpCAM + cancer cells, were detected using in vitro expansion with the HLA-A*11:01 restrictive SVCVNLYH neoantigen. Furthermore, the CD8 + T cell response to SMAD4 P130L was diminished following remarkably decreased numbers of CD8 + T CM in MPE samples. In conclusion, CD8 + T cells responding to WT1 or SMAD4 P130L neoantigen expressed in EpCAM + pancreatic cancer cells were detected in MPE. A tumor antigen-specific immune response would provide novel insight into the MPE microenvironment.
MEMBER ACCOUNT
登录成功会直接打开下一页。